SYNTHESIS OF CATIONIC STEROID COMPOUNDS FOR DETECTION OF BACTERIAL INFECTIONS
SYNTHESIS OF CATIONIC STEROID COMPOUNDS FOR DETECTION OF BACTERIAL INFECTIONS
批准号:
9090097
负责人:
Buck E. Rogers
金额:
$22.81万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-01 至 2018-06-30
关键词:
AbscessAcidsAcuteAffinityAminesAnatomyAntibiotic TherapyAntibioticsBacteriaBacterial InfectionsBacterial ProteinsBindingBlood VesselsCause of DeathChelating AgentsChronicCiprofloxacinCitratesClinicalClinical ManagementCommunicable DiseasesDetectionDevelopmentDiscipline of Nuclear MedicineEnsureEukaryotic CellEvaluationFever of Unknown OriginGoalsGram-Negative BacteriaHealthImageImmunocompromised HostImplantInfectionInflammationKanamycinLabelLeukocytesLungLung InflammationMembraneModelingMonitorMorphologyMycosesOsteomyelitisOximesOxyquinolineParentsPatientsPeptide FragmentsPeptidesPhotonsPositronPositron-Emission TomographyPostoperative PeriodRadioactiveRadioimmunoconjugateRadiolabeledRadiopharmaceuticalsSiteSpecificitySterilitySteroidsSymptomsThymidine KinaseUltrasonographyVirus DiseasesX-Ray Computed Tomographyantimicrobialantimicrobial drugantimicrobial peptidebasecancer imagingchemokinedesignfluorodeoxyglucoseimaging agentmortalitymouse modelnovelnucleoside analogradiotracerresponsesingle photon emission computed tomographytriazacyclononaneuptakewhole body imaging
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Infectious diseases remain a major health problem and cause of death worldwide. The identification and localization of sites of infection in patients
is a critical step in their clinical management, particularly when localized symptoms of the infection are not present. The prompt identification of infections can be cured with proper treatment, while delays can result in mortality. Anatomic imaging using ultrasound or computed tomography can be used for identification if local symptoms are present, however, they cannot differentiate between an infection and inflammation. Whole body scans in nuclear medicine imaging would be advantageous for imaging when there are no local symptoms of infection. There are a variety of radiopharmaceuticals that are used to detect infection and inflammation; however, it has been shown that the majority of these probes cannot distinguish between infection and inflammation. Therefore, the development of an imaging agent that is specific for detection of bacterial infections in a variety of clinical contexts would be highly significant. Soe progress has been made on the development of probes for the specific detection of viral, fungal, and bacterial infections. The use of radiolabeled antibiotics such as ciprofloxacin, kanamycin, and sulphanilamide for the detection of bacterial infections has been investigated, but there is concern about their specificity. The goal of this study is to develop a PET imaging agent based on a novel class of antimicrobial agents for the specific detection of bacterial infections. These novel antimicrobial agents are cationic steroid compounds, designed to mimic the morphology of endogenous antimicrobial peptides and have been shown to be effective against both Gram-positive and Gram-negative bacteria. These compounds display high and selective affinity for bacterial membranes over eukaryotic cells. In these studies, we will modify the cationic steroid antibiotics (CSAs) with the 1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid (NOTA) chelator such that they can be radiolabeled with the positron-emitter, 64Cu. These conjugates will be evaluated to ensure that they maintain their activity against bacteria and then radiolabeled with 64Cu to determine uptake and affinity in bacterial cultures. The resulting radiolabeled conjugates will then be evaluated in a lung infection model in sterile inflammation to determine the specificity of the agent. The specific aims of the proposal are: 1.) Synthesize and evaluate CSAs that have been conjugated to NOTA and 2.) Evaluate 64Cu-NOTA-CSA conjugates in a lung infection model.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.
预防卡氏肺孢子虫肺炎的剂量、间隔时间和药物比较。
DOI:
10.1128/aac.32.5.623
发表时间:
1988
期刊:
Antimicrobial agents and chemotherapy
影响因子:
4.9
作者:
[Hughes,WT]
通讯作者:
Hughes,WT
Small Molecule GPCR Ligands for Oncologic Imaging
-
批准号:9977505
-
项目类别:
-
资助金额:$19.68万
-
财政年份:2020
-
负责人:Buck E. Rogers
-
依托单位:
The PET Radiotracer Translation and Resource Center (PET-RTRC) Training & Dissemination
-
批准号:10715917
-
项目类别:
-
资助金额:$14.54万
-
财政年份:2018
-
负责人:Buck E. Rogers
-
依托单位:
DEVELOPMENT OF A MICRORT SYSTEM
-
批准号:7826778
-
项目类别:
-
资助金额:$35.67万
-
财政年份:2009
-
负责人:Buck E. Rogers
-
依托单位:
DEVELOPMENT OF PET RADIOPHARMACEUTICALS TARGETING GRPR
-
批准号:7731138
-
项目类别:
-
资助金额:$34.01万
-
财政年份:2009
-
负责人:Buck E. Rogers
-
依托单位:
DEVELOPMENT OF PET RADIOPHARMACEUTICALS TARGETING GRPR
-
批准号:8077958
-
项目类别:
-
资助金额:$31.95万
-
财政年份:2009
-
负责人:Buck E. Rogers
-
依托单位:
DEVELOPMENT OF PET RADIOPHARMACEUTICALS TARGETING GRPR
-
批准号:8266454
-
项目类别:
-
资助金额:$31.95万
-
财政年份:2009
-
负责人:Buck E. Rogers
-
依托单位:
Somatostatin Receptor Based PET Imaging of Gene Transfer
-
批准号:7015559
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2005
-
负责人:Buck E. Rogers
-
依托单位:
Somatostatin Receptor Based PET Imaging of Gene Transfer
-
批准号:6856960
-
项目类别:
-
资助金额:$31.84万
-
财政年份:2005
-
负责人:Buck E. Rogers
-
依托单位:
Somatostatin Receptor Based PET Imaging of Gene Transfer
-
批准号:7227724
-
项目类别:
-
资助金额:$28.86万
-
财政年份:2005
-
负责人:Buck E. Rogers
-
依托单位:
Somatostatin Receptor Based PET Imaging of Gene Transfer
-
批准号:7433269
-
项目类别:
-
资助金额:$28.88万
-
财政年份:2005
-
负责人:Buck E. Rogers
-
依托单位:
Pulmonary Transgene Expression Imaging with PET
-
批准号:7329827
-
项目类别:
-
资助金额:$44.49万
-
财政年份:2004
-
负责人:Buck E. Rogers
-
依托单位:
Heat Induced Suicide Gene Therapy for H and N Cancer
-
批准号:6867829
-
项目类别:
-
资助金额:$6.0万
-
财政年份:2004
-
负责人:Buck E. Rogers
-
依托单位:
Heat Induced Suicide Gene Therapy for H and N Surgery
-
批准号:6954640
-
项目类别:
-
资助金额:$6.0万
-
财政年份:2004
-
负责人:Buck E. Rogers
-
依托单位:
Core--In Vivo Procedures Core
-
批准号:6989571
-
项目类别:
-
资助金额:$17.73万
-
财政年份:2004
-
负责人:Buck E. Rogers
-
依托单位:
Core--In Vivo Procedures Core
-
批准号:7664000
-
项目类别:
-
资助金额:$30.74万
-
财政年份:--
-
负责人:Buck E. Rogers
-
依托单位:
Core--In Vivo Procedures Core
-
批准号:7475637
-
项目类别:
-
资助金额:$30.54万
-
财政年份:--
-
负责人:Buck E. Rogers
-
依托单位:
Core--In Vivo Procedures Core
-
批准号:7258802
-
项目类别:
-
资助金额:$18.8万
-
财政年份:--
-
负责人:Buck E. Rogers
-
依托单位:
Core--In Vivo Procedures Core
-
批准号:7089932
-
项目类别:
-
资助金额:$18.11万
-
财政年份:--
-
负责人:Buck E. Rogers
-
依托单位:
国内基金
海外基金
登录
查看更多内容
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
-
批准号:22007039
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:王黎明
-
依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:朱义广
-
依托单位:
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
-
批准号:21372217
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:袁伟成
-
依托单位:
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
-
批准号:21172061
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2011
-
负责人:许新华
-
依托单位:
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
-
批准号:21176225
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:童少平
-
依托单位:
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
-
批准号:81072511
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:严江伟
-
依托单位:
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
-
批准号:30660215
-
项目类别:地区科学基金项目
-
资助金额:21.0万元
-
批准年份:2006
-
负责人:王世范
-
依托单位: